Quent Capital, LLC Seagen Inc. Transaction History

Quent Capital, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Jun 14, 2024	SELL	$191.51 - $216.16 $1,532 - $1,729	-8 Reduced 16.33%	41 $8,000
Q3 2023 Oct 10, 2023	SELL	$191.51 - $216.16 $1,532 - $1,729	-8 Reduced 16.33%	41 $8,000
Q2 2023 Jun 14, 2024	BUY	$187.64 - $206.25 $1,313 - $1,443	7 Added 16.67%	49 $9,000
Q2 2023 Jul 10, 2023	BUY	$187.64 - $206.25 $1,313 - $1,443	7 Added 16.67%	49 $9,000
Q1 2023 Jun 14, 2024	BUY	$127.59 - $203.08 $5,358 - $8,529	42 New	42 $8,000

Q1 2023 Apr 05, 2023	BUY	$127.59 - $203.08 $1,403 - $2,233	11 Added 35.48%	42 $8,000
Q4 2022 Jan 19, 2023	SELL	$117.37 - $139.17 $9,859 - $11,690	-84 Reduced 73.04%	31 $0
Q3 2022 Nov 10, 2022	BUY	$135.27 - $180.11 $10,551 - $14,048	78 Added 210.81%	115 $16,000
Q2 2022 Aug 08, 2022	BUY	$108.81 - $179.33 $1,632 - $2,689	15 Added 68.18%	37 $7,000
Q1 2022 May 12, 2022	BUY	$119.61 - $157.85 $956 - $1,262	8 Added 57.14%	22 $3,000
Q4 2021 Feb 28, 2022	BUY	$142.57 - $190.86 $1,995 - $2,672	14 New	14 $2,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Quent Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Quent Capital, LLC with notifications on news.